PTGX – Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc.PTGX
$133.62Name : Protagonist Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $8,721,065,984.00
EPSttm : 4.73
Protagonist Therapeutics, Inc.
$133.62
1.94%$2.64
PTGX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
16.82
Margin Of Safety %
-2
Put/Call OI Ratio
0.37
EPS Next Q Diff
-3.08
EPS Last/This Y
7.63
EPS This/Next Y
-5.19
Price
136.18
Target Price
181.73
Analyst Recom
1.07
Performance Q
-10.36
Upside
-55.0%
Beta
1.23
Ticker: PTGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | PTGX | 144.92 | 0.35 | 0.76 | 6844 |
| 2026-10-13 | PTGX | 139.03 | 0.36 | 0.42 | 6912 |
| 2026-10-14 | PTGX | 136.35 | 0.36 | 1.07 | 6919 |
| 2026-10-15 | PTGX | 136.39 | 0.36 | 0.06 | 6918 |
| 2026-10-16 | PTGX | 128.8 | 0.35 | 0.59 | 6959 |
| 2026-10-19 | PTGX | 134.47 | 0.35 | 0.00 | 6379 |
| 2026-10-20 | PTGX | 138.07 | 0.35 | 0.00 | 6386 |
| 2026-10-21 | PTGX | 138.13 | 0.34 | 0.00 | 6444 |
| 2026-10-22 | PTGX | 139.38 | 0.34 | 0.00 | 6469 |
| 2026-10-23 | PTGX | 138.43 | 0.34 | 0.00 | 6512 |
| 2026-10-26 | PTGX | 140.11 | 0.34 | 0.00 | 6553 |
| 2026-10-27 | PTGX | 141.02 | 0.34 | 0.42 | 6551 |
| 2026-10-28 | PTGX | 142.03 | 0.34 | 4.67 | 6566 |
| 2026-10-29 | PTGX | 144.32 | 0.34 | 0.50 | 6575 |
| 2026-10-30 | PTGX | 144.96 | 0.34 | 1.82 | 6577 |
| 2026-11-02 | PTGX | 139.37 | 0.34 | 0.25 | 6601 |
| 2026-11-03 | PTGX | 140.4 | 0.34 | 0.50 | 6602 |
| 2026-11-04 | PTGX | 143.32 | 0.34 | 0.60 | 6615 |
| 2026-11-05 | PTGX | 135.08 | 0.34 | 2.06 | 6622 |
| 2026-11-06 | PTGX | 131.81 | 0.34 | 24.50 | 6639 |
| 2026-11-09 | PTGX | 135.9 | 0.37 | 5.00 | 6742 |
| 2026-11-10 | PTGX | 136.23 | 0.37 | 999.99 | 6747 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | PTGX | 144.91 | 519.3 | - | 4.79 |
| 2026-10-13 | PTGX | 138.49 | 522.6 | - | 4.76 |
| 2026-10-14 | PTGX | 136.31 | 522.6 | - | 4.76 |
| 2026-10-15 | PTGX | 136.50 | 522.6 | - | 4.76 |
| 2026-10-16 | PTGX | 128.80 | 508.3 | - | 4.66 |
| 2026-10-19 | PTGX | 134.45 | 508.4 | - | 4.66 |
| 2026-10-20 | PTGX | 134.45 | 508.4 | - | 4.66 |
| 2026-10-21 | PTGX | 138.00 | 508.4 | - | 4.66 |
| 2026-10-22 | PTGX | 139.49 | 508.4 | - | 4.66 |
| 2026-10-23 | PTGX | 138.40 | 508.4 | - | 4.66 |
| 2026-10-26 | PTGX | 140.33 | 529.2 | - | 4.77 |
| 2026-10-27 | PTGX | 141.07 | 529.2 | - | 4.77 |
| 2026-10-28 | PTGX | 142.05 | 529.2 | - | 4.77 |
| 2026-10-29 | PTGX | 144.23 | 529.2 | - | 4.77 |
| 2026-10-30 | PTGX | 144.93 | 529.2 | - | 4.77 |
| 2026-11-02 | PTGX | 139.37 | 529.2 | - | 4.77 |
| 2026-11-03 | PTGX | 140.44 | 529.2 | - | 4.77 |
| 2026-11-04 | PTGX | 143.52 | 529.2 | - | 4.77 |
| 2026-11-05 | PTGX | 135.20 | 529.2 | - | 4.77 |
| 2026-11-06 | PTGX | 132.02 | 529.2 | - | 4.77 |
| 2026-11-09 | PTGX | 135.90 | 26.9 | - | 4.77 |
| 2026-11-10 | PTGX | 136.18 | 94.8 | - | 5.58 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | PTGX | -11.35 | -4.14 | 15.27 |
| 2026-10-13 | PTGX | -11.35 | -4.14 | 15.27 |
| 2026-10-14 | PTGX | -11.35 | -4.14 | 15.27 |
| 2026-10-15 | PTGX | -11.35 | -4.14 | 15.27 |
| 2026-10-16 | PTGX | -11.35 | -4.14 | 15.27 |
| 2026-10-19 | PTGX | -11.35 | -4.17 | 15.27 |
| 2026-10-20 | PTGX | -11.35 | -4.17 | 15.27 |
| 2026-10-21 | PTGX | -11.35 | -4.17 | 15.27 |
| 2026-10-22 | PTGX | -11.31 | -4.17 | 15.27 |
| 2026-10-23 | PTGX | -11.31 | -4.17 | 15.27 |
| 2026-10-26 | PTGX | -11.31 | -4.21 | 15.27 |
| 2026-10-27 | PTGX | -11.31 | -4.21 | 16.82 |
| 2026-10-28 | PTGX | -11.31 | -4.21 | 16.82 |
| 2026-10-29 | PTGX | -11.31 | -4.21 | 16.82 |
| 2026-10-30 | PTGX | -11.31 | -4.21 | 16.82 |
| 2026-11-02 | PTGX | -11.31 | -5.75 | 16.82 |
| 2026-11-03 | PTGX | -11.31 | -5.75 | 16.82 |
| 2026-11-05 | PTGX | -11.31 | -5.75 | 16.82 |
| 2026-11-06 | PTGX | -11.31 | -5.75 | 16.82 |
| 2026-11-09 | PTGX | -11.31 | -6.16 | 16.82 |
| 2026-11-10 | PTGX | -11.31 | -6.16 | 16.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.07
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.01
Insider Transactions
-11.31
Institutional Transactions
-6.16
Beta
1.23
Average Sales Estimate Current Quarter
127
Average Sales Estimate Next Quarter
64
Fair Value
133.43
Quality Score
76
Growth Score
37
Sentiment Score
14
Actual DrawDown %
15.3
Max Drawdown 5-Year %
-81
Target Price
181.73
P/E
28.86
Forward P/E
PEG
P/S
16.12
P/B
8.19
P/Free Cash Flow
81.48
EPS
4.72
Average EPS Est. Cur. Y
5.58
EPS Next Y. (Est.)
0.39
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
62.04
Relative Volume
0.77
Return on Equity vs Sector %
5.3
Return on Equity vs Industry %
25
EPS 1 7Days Diff
0.8
EPS 1 30Days Diff
0.79
EBIT Estimation
◆
PTGX
Healthcare
$136.26
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
45.6
Range 1M
33.6%
Sup Dist
3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
352.8%
EPS NY
-100.5%
52W%
69.3%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-42.1% upside
Upside
-42.1%
Quality
76
MoS
-2%
PTGX — P/E HistoricalBiotechnology
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 149
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX
Latest News
—
Caricamento notizie per PTGX…
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading